Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response

Gut and Liver

Volumn 7, Issue 6, 2013, Pages 712-718

  Kwon, Dae Hun ^a   Kim, In Hee ^a   Choung, Bum Su ^a   Ahn, Dae Seon ^a   Yoo, Sun Ho ^a   Park, Sang Bae ^a   Lee, Seok ^a   Kim, Seong Hun ^a   Kim, Sang Wook ^a   Im, Yong Jin ^b  

^a Chonbuk National University Medical School   (South Korea)

^b Jeonbuk National University   (South Korea)

Author keywords

Chronic; Entecavir; Hepatitis B; Partial; Response

Indexed keywords

ENTECAVIR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARTIAL VIROLOGIC RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; SERUM; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY; VIRUS RESISTANCE;

CHRONIC; ENTECAVIR; HEPATITIS B; PARTIAL; RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; VIRAL LOAD;

EID: 84888622039     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.6.712     Document Type: Article

References (18)

1. European Association For The Study of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162.
3. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56 Suppl 1:S112-S122.
4. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34(4 Pt 1):785-791.
5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
6. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
7. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
8. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
9. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
10. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist 2011;4:55-64.
11. Han KH, Hong SP, Choi SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011;16:77-87.
12. Heo J, Park JY, Lee HJ, et al. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir Ther 2012;17:1563-1570.
13. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500.
14. European Association For The Study of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
15. Chon YE, Kim SU, Lee CK, et al. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir Ther 2011;16:469-477.
16. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-451.
17. Ko SY, Choe WH, Kwon SY, et al. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand J Gastroenterol 2012;47:1362-1367.
18. Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat 2012;19:213-219.